BACKGROUND:GMZ2 is a hybrid protein consisting of the N-terminal region of the glutamate-rich protein fused in frame to the C-terminal region of merozoite surface protein 3 (MSP3). GMZ2 formulated in Al(OH)3 has been tested in 3 published phase 1 clinical trials. The GMZ2/alum formulation showed good safety, tolerability, and immunogenicity, but whether antibodies elicited by vaccination are functional is not known. METHODS: Serum samples prior to vaccination and 4 weeks after the last vaccination from the 3 clinical trials were used to perform a comparative assessment of biological activity against Plasmodium falciparum. RESULTS: We showed that the maximum level of immunoglobulin G (IgG) antibodies obtained by GMZ2 vaccination is independent of ethnicity, time under malaria-exposure, and vaccine dose and that GMZ2 elicits high levels of functionally active IgG antibodies. Both, malaria-naive adults and malaria-exposed preschool children elicit vaccine-specific antibodies with broad inhibitory activity against geographically diverse P. falciparum isolates. Peptide-mapping studies of IgG subclass responses identified IgG3 against a peptide derived from MSP3 as the strongest predictor of antibody-dependent cellular inhibition. CONCLUSIONS: These findings suggest that GMZ2 adjuvanted in Al(OH)3 elicits high levels of specific and functional antibodies with the capacity to control parasite multiplication.
RCT Entities:
BACKGROUND:GMZ2 is a hybrid protein consisting of the N-terminal region of the glutamate-rich protein fused in frame to the C-terminal region of merozoite surface protein 3 (MSP3). GMZ2 formulated in Al(OH)3 has been tested in 3 published phase 1 clinical trials. The GMZ2/alum formulation showed good safety, tolerability, and immunogenicity, but whether antibodies elicited by vaccination are functional is not known. METHODS: Serum samples prior to vaccination and 4 weeks after the last vaccination from the 3 clinical trials were used to perform a comparative assessment of biological activity against Plasmodium falciparum. RESULTS: We showed that the maximum level of immunoglobulin G (IgG) antibodies obtained by GMZ2 vaccination is independent of ethnicity, time under malaria-exposure, and vaccine dose and that GMZ2 elicits high levels of functionally active IgG antibodies. Both, malaria-naive adults and malaria-exposed preschool children elicit vaccine-specific antibodies with broad inhibitory activity against geographically diverse P. falciparum isolates. Peptide-mapping studies of IgG subclass responses identified IgG3 against a peptide derived from MSP3 as the strongest predictor of antibody-dependent cellular inhibition. CONCLUSIONS: These findings suggest that GMZ2 adjuvanted in Al(OH)3 elicits high levels of specific and functional antibodies with the capacity to control parasite multiplication.
Authors: Jean Claude Dejon-Agobe; Ulysse Ateba-Ngoa; Albert Lalremruata; Andreas Homoet; Julie Engelhorn; Odilon Paterne Nouatin; Jean Ronald Edoa; José F Fernandes; Meral Esen; Yoanne Darelle Mouwenda; Eunice M Betouke Ongwe; Marguerite Massinga-Loembe; Stephen L Hoffman; B Kim Lee Sim; Michael Theisen; Peter G Kremsner; Ayôla A Adegnika; Bertrand Lell; Benjamin Mordmüller Journal: Clin Infect Dis Date: 2019-09-27 Impact factor: 9.079
Authors: Odilon Nouatin; Ulysse Ateba Ngoa; Javier Ibáñez; Jean Claude Dejon-Agobe; Benjamin Mordmüller; Jean Ronald Edoa; Fabrice Mougeni; Sina Brückner; Aurore Bouyoukou Hounkpatin; Meral Esen; Michael Theisen; Kabirou Moutairou; Stephen L Hoffman; Saadou Issifou; Adrian J F Luty; Marguerite M Loembe; Selidji Todagbé Agnandji; Bertrand Lell; Peter G Kremsner; Ayôla Akim Adegnika Journal: Vaccine Date: 2020-05-05 Impact factor: 3.641
Authors: Sylvester Dassah; Bright Adu; Régis W Tiendrebeogo; Susheel K Singh; Fareed K N Arthur; Sodiomon B Sirima; Michael Theisen Journal: Front Immunol Date: 2022-06-02 Impact factor: 8.786
Authors: Mark Kaddumukasa; Catherine Lwanira; Allan Lugaajju; Elly Katabira; Kristina E M Persson; Mats Wahlgren; Fred Kironde Journal: PLoS One Date: 2015-04-23 Impact factor: 3.240
Authors: David Llewellyn; Kazutoyo Miura; Michael P Fay; Andrew R Williams; Linda M Murungi; Jianguo Shi; Susanne H Hodgson; Alexander D Douglas; Faith H Osier; Rick M Fairhurst; Mahamadou Diakite; Richard J Pleass; Carole A Long; Simon J Draper Journal: Sci Rep Date: 2015-09-16 Impact factor: 4.379
Authors: Karen E S Hamre; Bartholomew N Ondigo; James S Hodges; Sheetij Dutta; Michael Theisen; George Ayodo; Chandy C John Journal: Am J Trop Med Hyg Date: 2020-10-27 Impact factor: 3.707